Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.7K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.7K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

The Journal of experimental medicine·2026
Same author

A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.

Cancer research·2026
Same author

Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients.

Cancers·2025
Same author

Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma.

Cancers·2025
Same author

Impact of Venetoclax Treatment Schedule on Hematologic Recovery and Treatment Response in AML Patients Unfit for Intensive Chemotherapy.

Cancers·2025
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
Same journal

MIF-CD74 Signaling Defines a Brain-Specific Immune Vulnerability in Metastasis and Neurologic Disease.

Cancer research·2026
Same journal

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K

Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.

Phillip Thienger1, Dilara Akhoundova1,2, Mark A Rubin1,3

  • 1Department for Biomedical Research, University of Bern, Bern, Switzerland.

Cancer Research
|February 16, 2026
PubMed
Summary
This summary is machine-generated.

Loss of EZH2 in prostate cancer did not reverse lineage plasticity but promoted neuroendocrine differentiation by activating KLF transcription factors and altering androgen receptor binding. This rewires tumor transcriptional networks, impacting treatment strategies.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Experiment Videos

Last Updated: Feb 17, 2026

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Enhancer of zeste homolog 2 (EZH2) inhibition is explored to reverse prostate cancer lineage plasticity (LP) and resensitize tumors to androgen receptor (AR) inhibition.
  • Prostate cancer progression involves a transition toward a neuroendocrine (NE) phenotype, a process influenced by EZH2.

Purpose of the Study:

  • To investigate the mechanistic role of EZH2 in prostate cancer progression and the transition to a neuroendocrine phenotype.
  • To elucidate how EZH2 loss impacts lineage plasticity and transcription factor programs.

Main Methods:

  • Utilized a genetically engineered mouse model recapitulating prostate cancer progression to a NE phenotype.
  • Performed genetic deletion of Ezh2 to assess its effects on LP and NE differentiation.
  • Analyzed transcription factor (TF) activation, chromatin-binding landscape of AR, and genomic site association.

Main Results:

  • Genetic deletion of Ezh2 did not reverse LP but unexpectedly promoted NE differentiation.
  • Loss of EZH2 activated KLF transcription factor family members, contributing to transcriptional diversification.
  • EZH2 deletion altered AR chromatin binding, redirecting it to KLF-associated genomic sites, thus reshaping the AR cistrome.

Conclusions:

  • EZH2 loss in prostate cancer does not simply reverse LP but rather rewires transcriptional networks and alters the AR cistrome.
  • These findings refine the understanding of EZH2 function and have implications for the clinical deployment of EZH2 inhibitors in metastatic prostate cancer.
  • Further research is needed to define optimal strategies for using EZH2 inhibition to modulate tumor lineage dynamics.